Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Short-term Investments (2024 - 2026)

Barinthus Biotherapeutics filings provide 3 years of Short-term Investments readings, the most recent being $1.3 million for Q1 2026.

  • On a quarterly basis, Short-term Investments fell 8.9% to $1.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.3 million, a 8.9% decrease, with the full-year FY2025 number at $1.4 million, down 19.68% from a year prior.
  • Short-term Investments hit $1.3 million in Q1 2026 for Barinthus Biotherapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.7 million in Q4 2024 to a low of $1.3 million in Q1 2026.
  • Median Short-term Investments over the past 3 years was $1.4 million (2025), compared with a mean of $1.5 million.
  • Biggest five-year swings in Short-term Investments: decreased 19.68% in 2025 and later fell 8.9% in 2026.
  • Barinthus Biotherapeutics' Short-term Investments stood at $1.7 million in 2024, then dropped by 19.68% to $1.4 million in 2025, then decreased by 4.66% to $1.3 million in 2026.
  • The last three reported values for Short-term Investments were $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025) per Business Quant data.